{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:24:58Z","timestamp":1781263498366,"version":"3.54.1"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We explored the relationship between virological response in the first year of treatment and long-term outcomes in the BENCHMRK studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients failing antiretroviral treatment with 3-class resistant HIV-1 received double-blinded raltegravir (or placebo) with optimized background therapy (OBT) until week 156, followed by open-label raltegravir with OBT up to week 240. In this exploratory analysis of patients randomized to raltegravir, virological response over weeks 16\u201348 was categorized as continuous suppression (CS; viral RNA [vRNA] always &lt;50 copies\/ml), low-level viraemia (LLV; vRNA always &lt;400 copies\/ml, &gt;50 copies\/ml at least once), or not suppressed (NS; vRNA &gt;400 copies\/ml at least once). The association between these first-year vRNA response categories and baseline factors was analysed with univariate and multi-variate models. Virological and immunological outcomes for years 2\u20135 were assessed by first-year vRNA response category (observed failure approach).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline vRNA, baseline CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count and rapid viral decay (vRNA &lt;50 copies\/ml between weeks 2\u201312) correlated with first-year vRNA response ( P&lt;0.001); only rapid viral decay remained significant by multiple regression. Virological response rates were similar in the LLV and CS groups and lowest in the NS group. CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count increased through week 240 in the CS and LLV groups. Time to loss of virological response (confirmed vRNA \u2265400 copies\/ml) through week 240 did not support as strong a difference between the LLV and CS groups (log-rank P=0.11) as previously reported through weeks 156 and 192 ( P&lt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment-experienced patients on a raltegravir-based regimen with early LLV may have long-term virological and immunological benefit when their therapy is maintained.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2912","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T12:51:28Z","timestamp":1414414288000},"page":"307-315","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between First-Year Virological Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection"],"prefix":"10.1177","volume":"20","author":[{"given":"Joseph J","family":"Eron","sequence":"first","affiliation":[{"name":"University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cooper","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T","family":"Steigbigel","sequence":"additional","affiliation":[{"name":"State University of New York at Stony Brook, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[{"name":"Hospital Germans Trias i Pujol, Fundaci\u00f3n Irsicaixa, UAB, UVic-UCC, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yeni","sequence":"additional","affiliation":[{"name":"Hospital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M","family":"Strohmaier","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Barnard","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bach-Yen T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy","family":"Teppler","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BENCHMRK Study Teams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"key":"bibr1-IMP2912","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5453.646"},{"key":"bibr2-IMP2912","volume-title":"Prescribing information","author":"Isentress (raltegravir).","year":"2014"},{"key":"bibr3-IMP2912","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70093-8"},{"key":"bibr4-IMP2912","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708975"},{"key":"bibr5-IMP2912","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"bibr6-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis752"},{"key":"bibr7-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200210180-00008"},{"key":"bibr8-IMP2912","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.7.817"},{"key":"bibr9-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl092"},{"key":"bibr10-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31816a1d4f"},{"key":"bibr11-IMP2912","doi-asserted-by":"publisher","DOI":"10.1086\/423388"},{"key":"bibr12-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200208160-00008"},{"key":"bibr13-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir353"},{"key":"bibr14-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir728"},{"key":"bibr15-IMP2912","unstructured":"Eron J.J., Cooper D.A., Steigbigel R.T. Sustained antiretroviral effect of raltegravir at week 156 in the BENCHMRK studies, and exploratory analysis of late outcomes based on early virologic responses.\n                      17th Conference on Retroviruses and Opportunistic Infections\n                      . 16\u201319 February 2010, San Francisco, CA, USA. Abstract K-128."},{"key":"bibr16-IMP2912","unstructured":"Eron J.J., Cooper D.A., Steigbigel R.T. Exploratory analysis in the BENCHMRK studies at week 192: late outcomes based on early virologic responses. 6\n                      th IAS Conference on HIV Pathogenesis, Treatment and Prevention\n                      . 17\u201320 July 2011, Rome, Italy. Abstract MOPE225."},{"key":"bibr17-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit272"},{"key":"bibr18-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f12377"},{"key":"bibr19-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt428"},{"key":"bibr20-IMP2912","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120248109"},{"key":"bibr21-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks533"},{"key":"bibr22-IMP2912","unstructured":"Williams J.P., Hurst J., Robinson N. HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial. 7\n                      th IAS Conference on HIV Pathogenesis, Treatment and Prevention\n                      . 30 June\u20133 July 2013, Kuala Lumpur, Malaysia. Abstract WELBA04."},{"key":"bibr23-IMP2912","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 1 May 2014. Accessed 12 May 2014.) Available from http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"bibr24-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit529"},{"key":"bibr25-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200209270-00017"},{"key":"bibr26-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm516"},{"key":"bibr27-IMP2912","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/135965350801300707","volume":"13","author":"Geretti A.M.","year":"2008","journal-title":"Antivir Ther"},{"key":"bibr28-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000203"},{"key":"bibr29-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu019"},{"key":"bibr30-IMP2912","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182364513"},{"key":"bibr31-IMP2912","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu020"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:11Z","timestamp":1777380731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.3851\/IMP2912"],"URL":"https:\/\/doi.org\/10.3851\/imp2912","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}